Large Cell Neuroendocrine Carcinoma of the Bladder with Adenocarcinomatous Component.
Journal
Case reports in urology
ISSN: 2090-696X
Titre abrégé: Case Rep Urol
Pays: United States
ID NLM: 101580193
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
05
2020
revised:
05
09
2020
accepted:
28
09
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
Large cell neuroendocrine carcinoma (LCNC) is one of the rarest types of bladder cancer occurring in <1%. Either pure or mixed with another component, it remains one of the most aggressive types of bladder cancer. We report a case of LCNC of the bladder with an adenocarcinomatous component. The patient was a 64-year-old smoker male, who presented for the first time with dysuria and hematuria. A bladder tumor invading the anterior and right lateral bladder walls was discovered, without any secondary localizations. Tumor biopsy showed an LCNC with adenocarcinomatous components. The patient was treated by recurrent tumor resections, chemotherapy, and radiotherapy. No improvement was noted despite close follow-up and adequate treatment. Neuroendocrine bladder tumor is known to have an aggressive, rapid, and disadvantageous evolution. Multiple case reports were published so far, and a recent review was conducted in March 2020 by Sanguedolce et al. (2020). More cases are needed to establish the best management plan for this type of tumor.
Identifiants
pubmed: 33083089
doi: 10.1155/2020/8827646
pmc: PMC7557901
doi:
Types de publication
Case Reports
Langues
eng
Pagination
8827646Informations de copyright
Copyright © 2020 Rami Halabi et al.
Déclaration de conflit d'intérêts
All authors declare no conflicts of interest exist.
Références
Anticancer Res. 2008 Mar-Apr;28(2B):1369-72
pubmed: 18505081
Mod Pathol. 1998 Oct;11(10):1016-20
pubmed: 9796733
Arch Pathol Lab Med. 1986 Nov;110(11):1062-6
pubmed: 3778122
Arch Esp Urol. 2011 Mar;64(2):105-13
pubmed: 21399243
Int J Urol. 2008 Dec;15(12):1080-3
pubmed: 19120517
Am J Clin Pathol. 2007 Nov;128(5):733-9
pubmed: 17951193
Am J Surg Pathol. 1987 Aug;11(8):606-17
pubmed: 2441615
J Surg Case Rep. 2017 May 11;2017(5):rjw179
pubmed: 28560016
Clin Genitourin Cancer. 2013 Jun;11(2):73-7
pubmed: 23266053
Am J Dermatopathol. 2009 Apr;31(2):166-9
pubmed: 19318803
Pathol Res Pract. 2003;199(8):559-63
pubmed: 14533941
Acta Cytol. 2010 May-Jun;54(3):303-10
pubmed: 20518415
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Arch Pathol Lab Med. 2002 Oct;126(10):1229-32
pubmed: 12296766
Cancer Manag Res. 2018 Oct 11;10:4479-4489
pubmed: 30349380
J Clin Pathol. 2004 Mar;57(3):318-20
pubmed: 14990609
Curr Urol. 2013 Feb;7(3):155-9
pubmed: 24917779
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Urol. 2005 Jul;174(1):93-6
pubmed: 15947585
Surg Neurol Int. 2011;2:84
pubmed: 21748036
Clujul Med. 2017;90(1):13-17
pubmed: 28246491
Pan Afr Med J. 2018 Jun 14;30:134
pubmed: 30374380
Pathol Int. 2006 Nov;56(11):688-93
pubmed: 17040293
Case Rep Med. 2017;2017:4812453
pubmed: 28115940
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Anticancer Res. 2020 May;40(5):2439-2447
pubmed: 32366387